Published in March 2022 in the journal Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (available online in December 2021), this study used in-vitro analysis and in-vivo (mice) to study the effects of CBN on the major indicators of glaucoma in humans.
The indicators studied were: 1. increased intraocular pressure (IOP), 2. degeneration of RGC (retinal ganglion cells), and 3. optical nerve (ON) damage.
The study showed that CBN protected mouse retinal ganglion precursor-like cells from pressure-induced toxicity. It also showed that CBN improved pattern electroretinogram (pERG) amplitudes and reduced IOP in a rat model of glaucoma.
The authors concluded: "CBN promotes neuroprotection, abrogates changes in ECM protein, and normalizes the IOP levels in the eye. Therefore, our observations in the present study indicate a therapeutic potential for CBN in the treatment of glaucoma."
The paper abstract is here at ScienceDirect.com